CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of ovarian cancer.
  
  LEARNING OBJECTIVES

  • Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and as appropriate, counsel patients regarding personalized treatment recommendations.
  • Assess available clinical trial data with and newly adapted indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC to optimally and appropriately incorporate these agents into management algorithms.
  • Evaluate the biological rationale for and published research data with PARP inhibitors in combination with other systemic therapies, and consider the current and future clinical and research implications of these findings for OC management.
  • Appraise relevant biological and patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
  • Recognize the rationale for targeting folate receptor alpha (FRα) in OC, and determine effective methods to test for this newly relevant biomarker.
  • Understand the mechanism of action of and current research findings with antibody-drug conjugates directed at FRα, and optimally integrate these agents into the care of patients with recurrent OC.
  • Appreciate side effects associated with various systemic therapies commonly employed in the management of OC, and use this information to develop supportive care plans for patients undergoing treatment with these agents.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for OC, and as appropriate, counsel patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Interview: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Interview: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 2.25 (audio) and 1.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology. 
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/SGO25Ovarian/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/SGO25Ovarian/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/SGO25Ovarian/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/SGO25Ovarian.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Kathleen N Moore, MD, MS
  Deputy Director
  Virginia Kerley Cade Chair in Developmental Therapeutics
  Co-Director, Cancer Therapeutics Program
  Stephenson Cancer Center at the University of Oklahoma HSC
  Associate Director, GOG Partners
  Board of Directors, GOG Foundation
  Board of Directors, ASCO
  Oklahoma City, Oklahoma
  
  Advisory Committees: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Blueprint Medicines, Caris Life Sciences, Corcept Therapeutics, Daiichi Sankyo Inc, Duality Biologics, Eisai Inc, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Janssen Biotech Inc, Lilly, Merck, Mersana Therapeutics Inc, Novartis, Regeneron Pharmaceuticals Inc, Schrödinger, Takeda Pharmaceuticals USA Inc, Verastem Inc, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: Allarity Therapeutics, Daiichi Sankyo Inc, GSK, ImmunoGen Inc, Schrödinger, Verastem Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics.
  
  Ritu Salani, MD, MBA
  Director, Division of Gynecologic Oncology
  Professor, Department of Obstetrics and Gynecology
  David Geffen School of Medicine at UCLA
  Los Angeles, California
  
  Advisory Committees: AbbVie Inc, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, Merck, Pfizer Inc; Nonrelevant Financial Relationships: Elsevier, UpToDate.
  
  Shannon N Westin, MD, MPH, FASCO, FACOG
  Professor
  Medical Director, Gynecologic Oncology Center
  Director, Early Drug Development
  Department of Gynecologic Oncology and Reproductive Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Clovis Oncology, Corcept Therapeutics, Daiichi Sankyo Inc, Eisai Inc, EQRx, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, Mersana Therapeutics Inc, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Seagen Inc, Verastem Inc, Vincerx Pharma, Zentalis Pharmaceuticals, ZielBio; Contracted Research (to Institution): AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings Inc, Clovis Oncology, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Zentalis Pharmaceuticals.
  
  MODERATOR
  Angeles Alvarez Secord, MD, MHSc
  Professor of Obstetrics and Gynecology, Gynecologic Oncology
  Director of Gynecologic Oncology Clinical Trials
  Duke Cancer Institute
  Durham, North Carolina
  
  Advisory Boards (Honoraria): AbbVie Inc; Advisory Boards (Uncompensated): AstraZeneca Pharmaceuticals LP, CanariaBio Inc, Clovis Oncology, Gilead Sciences Inc, GSK, ImmunoGen Inc, Imvax Inc, Merck, Mersana Therapeutics Inc, Natera Inc, OncoQuest Inc; Clinical Trial Steering Committees (Uncompensated): CanariaBio Inc (FLORA-5 trial, QPT-ORE-004 trial), VBL Therapeutics (OVAL trial); Clinical Trial and Research Grant Funding (to Institution): AbbVie Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Ellipses Pharma, Genentech, a member of the Roche Group, GSK, I-Mab Biopharma, ImmunoGen Inc, Karyopharm Therapeutics, Merck, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, OncoQuest Inc, Seagen Inc, VBL Therapeutics, Zentalis Pharmaceuticals; Nonrelevant Financial Relationships: GOG Foundation, Foundation for Women’s Cancer, National Clinical Trials Network, NRG Oncology, Society of Gynecologic Oncology, UpToDate.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, and Mural Oncology Inc.
  
  Release date: April 2025
  Expiration date: April 2026
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.